Navigation Links
ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
Date:2/22/2008

Presentation is One of Five Posters Scheduled for the 2008 Annual Meeting

of the Association for Research in Vision and Ophthalmology (ARVO)

IRVINE, Calif., Feb. 22 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced today the acceptance of an abstract describing the results of a study using Xibrom(TM) (bromfenac ophthalmic solution) 0.09% therapy in combination with Lucentis(R) (ranibizumab injection) in patients with age-related macular degeneration (AMD). According to the abstract, patients who received Xibrom required 1.6 +/- 0.69 injections of Lucentis during the six-month study period, while patients who received only Lucentis received 4.5 +/- 0.41 injections. Patients with Lucentis alone received significantly more (2.83 times) injections of ranibizumab (p=0.0002) than those receiving the combination. There was a numerical trend in favor of the combination treatment group on improvement in visual acuity but this difference did not achieve statistical significance. These data are expected to be presented at the ARVO 2008 annual meeting, which begins at the end of April.

The study results were gathered from 60 patients receiving Lucentis therapy for wet AMD. Patients were monitored monthly using optical coherence tomography (OCT) and fluorescein angiography. When leakage from vessels was detected, patients were re-injected with Lucentis. 30 patients received Xibrom dosed twice daily in addition to the Lucentis injection, and their results were compared to 30 patients who received Lucentis only. There were no adverse events associated with the extended topical administration of bromfenac. The study was designed as a retrospective case control series.

The clinical findings will be pre
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
2. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
3. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
6. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
7. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
8. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Mass. , May 21, 2013 /PRNewswire/ ... research and advisory firms for pharmaceutical and ... an emerging agent on key efficacy endpoints, ... progression, has the most influence over surveyed ... advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. ...
(Date:5/21/2013)... , May 21, 2013 iHealth ... manufacture of wireless personal healthcare products and a ... reach, announcing the release of two new fitness ... pressure monitors and scales: the Wireless Pulse Oximeter ... (Photo: http://photos.prnewswire.com/prnh/20130521/SF17618 ) iHealth ...
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
Breaking Medicine Technology:Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... Calif. and FORT WASHINGTON, Pa., Oct. 19, 2011 ... and fitness measurement utilizing biometric testing devices and ... in consumer focused, health engagement digital messaging, today ... solutions in the retail and non-retail markets. ...
... ATLANTA, Oct. 19, 2011 VaxyGen ... of an exclusive license and collaboration agreement with ... VaxyGen the exclusive license to a novel patent ... biopharmaceutical and vaccine products. In addition, VaxyGen and ...
Cached Medicine Technology:ADFLOW Health Networks and Stayhealthy Form Strategic Partnership to Deploy the Most Comprehensive Biometric Screening and Consumer Health Engagement Platform in U.S. 2ADFLOW Health Networks and Stayhealthy Form Strategic Partnership to Deploy the Most Comprehensive Biometric Screening and Consumer Health Engagement Platform in U.S. 3ADFLOW Health Networks and Stayhealthy Form Strategic Partnership to Deploy the Most Comprehensive Biometric Screening and Consumer Health Engagement Platform in U.S. 4VaxyGen Manufacturing Services LLC Announces Exclusive License and Collaborative Agreement with Georgia State University Research Foundation to Commercialize Novel Biological Process Development Patent, Expertise & Know-How 2VaxyGen Manufacturing Services LLC Announces Exclusive License and Collaborative Agreement with Georgia State University Research Foundation to Commercialize Novel Biological Process Development Patent, Expertise & Know-How 3
(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...
(Date:5/21/2013)... Global Proving Ground (GPG), a fast rising ... retailer of health and fitness supplements, are partnering up ... Island. “We cast the show by having millions ... our unique social networking platform,” states show’s creator James ... an island in the Pacific Ocean, where they must ...
(Date:5/21/2013)... Texas (PRWEB) May 21, 2013 ... With the help of Texas Counseling’s Sexuality and ... communication, and the development of healthier habits for ... workshops available for both couples and individuals at ... enhance their relationships and learn skills to develop ...
(Date:5/21/2013)... the roles two proteins, thrombospondin-1 and prosaposin, play ... has identified a five-amino acid fragment of prosaposin ... of prostate, breast and lung cancer. The findings ... metastasis in a variety of cancers. , ... at Boston Children,s Hospital, Vivek Mittal, PhD, at ...
(Date:5/21/2013)... University of Cincinnati (UC) researchers have identified a number ... help with earlier diagnosis and intervention in those who ... first of its kind and led by UC,s Bruce ... staff from Walter Reed National Military Medical Center at ... Orlando, Fla. , The DoDSR is a biological ...
Breaking Medicine News(10 mins):Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Biomarkers discovered for inflammatory bowel disease 2
... , , BOULDER, Colo., July 30 ... owning patented surgical technology that is emerging as a standard of ... quarter of fiscal year 2010. , , Net ... representing a 3% increase over net sales of $3.1 million for ...
... , SAO PAULO, July 30 Frost & Sullivan ... recipient of the 2009 Market Penetration Leadership Award ... offers a complete portfolio of solutions including digital and computed radiography, ... by the needs of customers willing to enter in the digital ...
... , , CHICAGO, July ... the world,s largest scientific/medical society dedicated to advancing research and ... of the human lifespan, unveils an innovative, technology-based fix to ... Increase the lifespan, or improve the healthspan, of all ...
... ... America, will award prizes to young filmmakers, 25 years of age and under, ... America. The top three winners will receive cash prizes of $5,000, $3,500 and ... 5-12 minutes creative films online, where the public will partake in the first ...
... ... provide students with an excellent option for a less expensive education in the thriving ... ... the nursing shortage creates opportunity for the qualified nurse, and online nursing degrees are ...
... DALLAS July 30, 2009 The typical dose ... is much too low to account for modern-day physiques, ... The finding, reported online and in the August edition ... important for those living in societies plagued by obesity, ...
Cached Medicine News:Health News:Encision Reports Profitable First Fiscal Quarter Results 2Health News:Encision Reports Profitable First Fiscal Quarter Results 3Health News:Encision Reports Profitable First Fiscal Quarter Results 4Health News:Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009 2Health News:Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009 3Health News:Obama White House Can Save $3.7 Trillion and Extend Lifespan 29+ Years, Predicts Revolutionary A4M Healthcare Plan 2Health News:Call to the Youth of America: Palms for Life Fund Launches Film Competition to Document Hunger in the United States 2Health News:All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 2Health News:Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report 2Health News:Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report 3
... Mumps IgM Enzyme-Linked Immunosorbent Assay ... qualitative detection of IgM antibody ... for the determination of immunological ... this kit have not been ...
The DSL 05-10-MUM Mumps IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Mumps virus in human serum. This assay is intended for in...
... announced the launch of the Chilli ... bi-directional cooled-tip catheter available in the United ... physicians the benefits of cooled ablation technology ... Boston Scientific Blazer(R) catheter platform. ,Cooled cardiac ...
... wire crosses the lesion first, independent of ... actions, including filter placement and retrieval, balloon ... the wire., ,Emboshield is designed to capture ... carotid stenting procedure, and it is the ...
Medicine Products: